Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARTIA XT vs AMVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cells during depolarization, leading to vasodilation and reduced myocardial contractility and conduction velocity, particularly at the AV node.
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
FDA-approved: hypertension,FDA-approved: chronic stable angina,FDA-approved: atrial fibrillation or flutter (rate control),Off-label: prevention of migraine,Off-label: anal fissure (topical)
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Diltiazem hydrochloride extended-release capsules (CARTIA XT) are administered orally. For hypertension and angina, the typical adult dose is 180–360 mg once daily, initially 180 mg once daily, titrated to response.
Intravenous: 500 mg every 6 hours.
Terminal half-life 3-4.5 hours; prolonged in hepatic impairment (up to 15 hours) or with cimetidine.
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Primarily hepatic via CYP3A4; extensive first-pass metabolism. Metabolites include desacetyldiltiazem (active, 25-50% potency).
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Renal (biliary/fecal minimal). 70-80% excreted as inactive metabolites in urine; 15% unchanged.
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
40-50% bound to albumin.
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
Vd 5-10 L/kg; reflects extensive tissue distribution (highly lipophilic).
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
IR: 30-40% (first-pass metabolism); ER (CARTIA XT): 30-40% relative to IR.
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
No specific dose adjustment is required for renal impairment. However, use with caution in patients with severe renal impairment (Cr Cl <30 m L/min) and monitor heart rate and blood pressure.
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
Contraindicated in acute hepatic injury. For mild to moderate hepatic impairment (Child-Pugh class A/B), reduce starting dose by 50% and titrate slowly. For severe hepatic impairment (Child-Pugh class C), use is not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Safety and efficacy in pediatric patients have not been established. No standard weight-based dosing guidelines are available.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
In elderly patients (≥65 years), start at the lower end of the dosing range (e.g., 120–180 mg once daily) due to increased potential for bradycardia and hypotension; titrate cautiously.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
None
None
Heart failure: may worsen systolic function due to negative inotropic effects,Sick sinus syndrome or AV block: risk of bradycardia, heart block,Concomitant beta-blocker use: increased risk of bradycardia, heart failure,Hepatic impairment: reduce dose,Renal impairment: use caution,Abrupt discontinuation: may cause angina exacerbation,Sinus bradycardia: monitor heart rate
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
Hypersensitivity to diltiazem or any component,Sick sinus syndrome (except with functioning pacemaker),Second- or third-degree AV block (except with pacemaker),Left ventricular systolic dysfunction (ejection fraction <40%) with pulmonary congestion,Severe hypotension (systolic BP <90 mm Hg),Concurrent use of ivabradine
None
Avoid grapefruit and grapefruit juice as they can increase diltiazem levels and risk of side effects. Avoid high-fat meals close to dosing as they may affect absorption. Limit alcohol intake as it may worsen hypotension or dizziness.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
FDA Pregnancy Category C. First trimester: No adequate studies; potential for embryotoxicity. Second and third trimesters: May cause fetal bradycardia, hypotension, hypoglycemia; risk of intrauterine growth restriction. Use only if benefit outweighs risk.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
Diltiazem is excreted in breast milk with a milk-to-plasma ratio of approximately 0.5-1.0. Limited data suggest low risk to infant, but consider monitoring for bradycardia and hypotension. Use with caution.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
No specific dose adjustments recommended; increased clearance in pregnancy may require dose titration based on clinical response. Monitor for hypotension and bradycardia. Use lowest effective dose.
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
CARTIA XT is a sustained-release formulation of diltiazem, a calcium channel blocker. Avoid use in patients with sick sinus syndrome or second/third-degree AV block without a pacemaker. Titrate slowly to prevent hypotension. Monitor heart rate and blood pressure regularly. Use with caution in hepatic or renal impairment. Can be used for rate control in atrial fibrillation but not for conversion. Swallow capsules whole; do not crush or chew.
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Take this medication exactly as prescribed, usually once daily. Swallow the capsule whole; do not crush, chew, or open it.,Do not stop taking this medication suddenly without consulting your doctor, as it may worsen your condition.,Avoid drinking grapefruit juice or eating grapefruit while taking this medication.,Inform your doctor if you experience dizziness, lightheadedness, slow heartbeat, swelling of ankles/feet, or shortness of breath.,This medication may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Keep a regular schedule for taking this medication to maintain consistent levels in your blood.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARTIA XT vs AMVAZ, answered by our medical review team.
CARTIA XT is a Calcium Channel Blocker that works by Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cells during depolarization, leading to vasodilation and reduced myocardial contractility and conduction velocity, particularly at the AV node.. AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARTIA XT and AMVAZ depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARTIA XT is: Diltiazem hydrochloride extended-release capsules (CARTIA XT) are administered orally. For hypertension and angina, the typical adult dose is 180–360 mg once daily, initially 180 mg once daily, titrated to response.. The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARTIA XT and AMVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARTIA XT is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate studies; potential for embryotoxicity. Second and third trimesters: May cause fetal bradycardia, hypotension, hypoglycemia; r. AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.